Live Breaking News & Updates on Investigational therapy

Stay informed with the latest breaking news from Investigational therapy on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Investigational therapy and stay connected to the pulse of your community

Stock Market | FinancialContent Business Page

Stock Market | FinancialContent Business Page
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.

James-sapirstein , Cystic-fibrosis-foundation , National-pancreas-foundation , First-wave-biopharma-inc , Nasdaq , Trial-enrollment-completed , Investigational-therapy , Exocrine-pancreatic , Wave-biopharma , First-wave-biopharma , Potential-solution

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...

Cambridge , Cambridgeshire , United-kingdom , Australia , Japan , United-states , New-zealand , Massachusetts , Boston , South-korea , Republic-of-korea , Matthew-deyoung

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today...

Boston , Massachusetts , United-states , Australia , Japan , Cambridge , Cambridgeshire , United-kingdom , New-zealand , Matthew-deyoung , Douglase-onsi , Prnewswire-leap-therapeutics-inc

Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress

Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Australia , Japan , United-states , Cambridge , Cambridgeshire , United-kingdom , New-zealand , South-korea , Republic-of-korea , Douglase-onsipresident , Matthew-deyounginvestor-relationsargot , Fiona-turkes

Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress

Median Progression-Free Survival of 11.3 months in first-line gastric cancer patients treated with DKN-01 plus tislelizumab and CAPOX, exceeding benchmarks in...

Australia , Japan , United-states , Cambridge , Cambridgeshire , United-kingdom , New-zealand , South-korea , Republic-of-korea , Matthew-deyoung , Fiona-turkes , Douglase-onsi

Leap Therapeutics to Present Positive New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ASCO GI Cancers Symposium

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...

Australia , Japan , United-states , New-zealand , Massachusetts , Cambridge , Cambridgeshire , United-kingdom , South-korea , Canada , Republic-of-korea , American

Leap Therapeutics to Present Positive New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ASCO GI Cancers Symposium

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...

Australia , Japan , United-states , New-zealand , Massachusetts , Cambridge , Cambridgeshire , United-kingdom , South-korea , Canada , Republic-of-korea , American

US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Huntington Disease

US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Huntington Disease
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Netherlands , Rupert-sandbrink , Drug-administration , Office-of-orphan-products-development , Orphan-drug-designation , Investigational-therapy , Leiden-bio-science-park , Orphan-products-development , Chief-medical-officer , நெதர்லாந்து , அலுவலகம்-ஆஃப்-ஆர்ஃபந்-ப்ராடக்ட்ஸ்-வளர்ச்சி , ஆர்ஃபந்-மருந்து-பதவி

Centre allocates Remdesivir supply to 19 States/UTs with high load of COVID-19 cases

Centre allocates Remdesivir supply to 19 States/UTs with high load of COVID-19 cases
ANI |
Updated: Apr 24, 2021 23:28 IST
New Delhi [India], April 24 (ANI): The central government on Saturday allocated supply of Remdesivir to 19 States/Union Territories with a high burden of COVID-19 cases.
"The escalation of serious COVID19 patients in hospitals for effective clinical management has also resulted in an increase in the demand of Remdesivir. While the States have been advised to promote the judicious use of the drug which is listed as an Investigational Therapy by the Ministry, they have also been advised to take action against possible hoarding and black marketing of the drug," reads a Health Ministry release.

New-delhi , Delhi , India , Sadananda-gowda , Department-of-pharmaceuticals , States-union-territories , Union-health-ministry , Twitter , Health-ministry , Union-territories , Investigational-therapy , Remdesivir-injection

Centre allocates Remdesivir supply to 19 States/UTs with high load of Covid-19 cases | India News

Export of Remdesivir has also been prohibited on April 11, 2021, in order to shore up domestic supplies
NEW DELHI: The central government on Saturday allocated supply of Remdesivir to 19 States/Union Territories with a high burden of Covid-19 cases.
"The escalation of serious Covid-19 patients in hospitals for effective clinical management has also resulted in an increase in the demand of Remdesivir. While the States have been advised to promote the judicious use of the drug which is listed as an Investigational Therapy by the ministry, they have also been advised to take action against possible hoarding and black marketing of the drug," reads a health ministry release.

Sadananda-gowda , Department-of-pharmaceuticals , States-union-territories , Union-health-ministry , Twitter , Union-territories , Investigational-therapy , Remdesivir-injection , Union-minister-sadananda-gowda , India , Ndia-news , Ndia-news-today